The Board of Directors of Sanofi India convened on February 25, 2026, to approve the Audited Financial Results for the Quarter and Financial Year ended December 31, 2025. The board recommended a final dividend of ₹48 per equity share, bringing the total dividend for the year to ₹123 per share. Furthermore, the board announced key changes in directorship, including the appointment of Mrs. Rajani Kesari and Ms. Sudipta Chakraborty, and the resignation of Mr. Rodolfo Hrosz.
Approval of Audited Financial Results for FY 2025
Sanofi India Limited announced the outcome of its Board Meeting held on Wednesday, February 25, 2026. The Board considered and approved the Audited Financial Results for the Quarter and the Financial Year ended December 31, 2025. The Statutory Auditors, M/s Price Waterhouse & Co. Chartered Accountants LLP, issued an unmodified opinion on these results.
Financial Highlights Summary (₹ in Million)
The results for the year ended December 31, 2025 (Audited), compared to the previous year:
- Total Income stood at ₹18,571 million, down from ₹20,297 million in FY 2024.
- Profit for the period/year from continuing operations was ₹3,267 million, up from ₹3,137 million.
- Total Comprehensive Income for the year reached ₹3,284 million.
- Basic and diluted earnings per share (Continuing Operations) were ₹141.85, compared to ₹136.21 previously.
Note 9 clarifies that the figures for the quarter ended December 31, 2025, are balancing figures between the audited full-year figures and the published unaudited year-to-date figures up to the third quarter.
Dividend Recommendation
The Board considered and recommended a final dividend of ₹48 per equity share of face value ₹10 for the Financial Year ended December 31, 2025. This is in addition to the interim dividend of ₹75 per equity share declared on October 29, 2025. Consequently, the total dividend for the year 2025 amounts to ₹123 per equity share.
Key Changes in Board of Directors
Pursuant to Regulation 30, the Board approved the following changes:
Appointments Subject to Shareholder Approval
- Appointment of Mrs. Rajani Kesari (DIN: 02384170) as an Additional and Independent Director for a term of Five (5) years, effective from April 01, 2026. Mrs. Kesari is a commerce graduate, Chartered Accountant, and former CFO of Nayara Energy Limited.
- Appointment of Ms. Sudipta Chakraborty (DIN: 07166912) as an Additional Director and Whole-time Director for a term of Three (3) years, effective from March 01, 2026. She will also be designated as a Key Managerial Personnel and Senior Management Personnel. Ms. Chakraborty brings over two decades of legal and compliance experience.
Resignation
- Mr. Rodolfo Hrosz (DIN: 09609832) resigned as Non-Executive Director, effective from the close of business hours on February 28, 2026, due to other pre-occupations and commitments. The Board recorded its appreciation for his contributions.
Accounting Notes Overview
Several key accounting treatments and events are noted:
- The results were reviewed by the Audit Committee on February 24, 2026, and approved by the Board on February 25, 2026.
- The company operates in a single segment: ‘Pharmaceutical Business’ (Note 6).
- Financial results for the Consumer Healthcare business are presented as discontinued operations for FY 2024, following its demerger effective June 1, 2024.
- Exceptional items for FY 2025 relate to personnel separation costs of ₹273 million (Note 4).
- An incremental impact of ₹58 million related to the implementation of the new Labour Codes has been recognized under Employee Benefits Expense in the current year (Note 5).
Source: BSE
